Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial-Reference-Cited by-同舟云学术

Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial

Published:2020-06 Issue:2 Volume:1 Page:e84-e92
ISSN:2666-5247
Container-title:The Lancet Microbe
language:en
Short-container-title:The Lancet Microbe

Author:

Diacon Andreas,Miyahara Sachiko,Dawson Rodney,Sun Xin,Hogg Evelyn,Donahue Kathleen,Urbanowski Michael,De Jager Veronique,Fletcher Courtney V,Hafner Richard,Swindells Susan,Bishai William

Publisher

Elsevier BV

Subject

Virology,Infectious Diseases,Microbiology (medical),Microbiology

Reference33 articles.

1. Isonicotinic acid hydrazide in tuberculosis in man;McDermott;Trans Assoc Am Physicians,1952

2. Comparison of bacteriostatic and bactericidal activity of isoniazid and ethionamide against Mycobacterium avium and Mycobacterium tuberculosis;Heifets;Am Rev Respir Dis,1991

3. Basic concepts in the chemotherapy of tuberculosis;Mitchison,1998

4. The early bactericidal activity of drugs in patients with pulmonary tuberculosis;Jindani;Am Rev Respir Dis,1980

5. Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days;Jindani;Am J Respir Crit Care Med,2003

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis;2024-05-13

2. Targeting Mycobacterium tuberculosis Persistence through Inhibition of the Trehalose Catalytic Shift;ACS Infectious Diseases;2024-03-14

3. Power to identify exposure‐response relationships in phase IIa pulmonary tuberculosis trials with multi‐dimensional bacterial load modeling;CPT: Pharmacometrics & Systems Pharmacology;2023-12-15

4. Molecular insights of hyaluronic acid – ethambutol and hyaluronic acid – isoniazid drug conjugates act as promising novel drugs for the treatment of tuberculosis;Journal of Biomolecular Structure and Dynamics;2022-03-16

5. Safety and pharmacokinetics-pharmacodynamics of a shorter tuberculosis treatment with high-dose pyrazinamide and rifampicin: a study protocol of a phase II clinical trial (HighShort-RP);BMJ Open;2022-03